ERBB2 and triple-negative breast carcinoma: When the panel was asked about the value of MRI as a standard procedure, in case of patients with human epidermal receptor 2 (HER2)-positive or triple-negative breast cancer (TNBC) planned to receive neoadjuvant therapy, 76% agreed that MRI being a standard modality to evaluate patients who might be chosen for breast conservation.